NFSG
DSGN icon

Newbridge Financial Services Group’s Design Therapeutics DSGN Stock Holding History

Newbridge Financial Services Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-300
Closed -$1.61K – 1152
2024
Q3 		$1.61K Buy
+300
New +$1.41K ﹤0.01% 580

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Newbridge Financial Services Group's DSGN Position: Q4 2024 in Review

Newbridge Financial Services Group sold out of Design Therapeutics (DSGN) in Q4 2024, closing a stake of 300 shares — an estimated $1.61K sold.

Newbridge Financial Services Group first reported a position in DSGN in Q3 2024 and held it in 1 quarter. The position peaked at $1.61K in Q3 2024. 95 funds tracked by Wall St. Rank hold DSGN as of Q4 2024.

  • Newbridge Financial Services Group reported no remaining Design Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Newbridge Financial Services Group sold 300 Design Therapeutics shares in Q4 2024, an estimated $1.61K.
  • Newbridge Financial Services Group first reported a position in Design Therapeutics in Q3 2024 and held it in 1 quarter.
  • Newbridge Financial Services Group's Design Therapeutics position peaked at $1.61K in Q3 2024.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2024.

Based on Newbridge Financial Services Group's 13F filing for Q4 2024, filed 28 Jan 2025.